Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $95.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 23.23% from the stock’s previous close. A […]

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been given an average rating of “Hold” by the eight analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation […]